Aegis Acquires Diagnovus
News Jan 12, 2015
Aegis Sciences Corporation announced the acquisition of Diagnovus LLC.
“The asset acquisition of Diagnovus allows Aegis to expand our healthcare laboratory testing services,” stated Aegis Founder, Chairman and CEO Dr. David L. Black. “The delivery of patient-specific genetic information to physicians will improve management of disease and prescribing of necessary medication.”
Diagnovus has developed multiple molecular diagnostic assays, including a buccal swab test which provides insight into an individual’s response to certain medications based on genetic structure. This valuable information may increase the quality of care by reducing the time required to find the optimal course of treatment.
“As a scientist and entrepreneur, I am proud to have our team join Aegis,” stated Diagnovus President and Co-Founder Dr. James Stover. “Aegis’ reputation and client base will allow us to offer our developed molecular diagnostic testing services to a much larger patient population.”
Compact Chemical Sensor Can Detect Substances from Over 100 Feet AwayNews
A chemical sensor prototype developed at the University of Michigan will be able to detect "single-fingerprint quantities" of substances from a distance of more than 100 feet away, and its developers are working to shrink it to the size of a shoe box. The development offers great potential for medical and law enforcement purposes.READ MORE
New Rapid Authentication Test for Chinese MedicinesNews
Scientists have developed a new method for rapid and simple authentication of Chinese herbal medicines. The new method will enable authentication of genuine and counterfeit products, classification of wild and cultivated types, as well as differentiation of geographical origins.READ MORE